Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Assessing the Incidence of Cardiac and Pulmonary Adverse Events (CAEs and PAEs) of Carfilzomib Treatment and the Risk Factors Associated with these Adverse Events in Patients with Plasma Cell Myeloma using the SEER-Medicare Database

Trial Profile

A Study Assessing the Incidence of Cardiac and Pulmonary Adverse Events (CAEs and PAEs) of Carfilzomib Treatment and the Risk Factors Associated with these Adverse Events in Patients with Plasma Cell Myeloma using the SEER-Medicare Database

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Nov 2019 Results assessing cardiac adverse events (CAEs) and pulmonary adverse events (PAEs) associated with carfilzomib in patients with multiple myeloma were published in the Cancer
    • 28 Dec 2017 New trial record
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top